Compare BWB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWB | ZVRA |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.1M | 562.2M |
| IPO Year | N/A | 2015 |
| Metric | BWB | ZVRA |
|---|---|---|
| Price | $21.44 | $11.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $21.67 | ★ $23.00 |
| AVG Volume (30 Days) | 175.9K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $24.57 | $37.27 |
| Revenue Next Year | $12.35 | $53.42 |
| P/E Ratio | ★ $12.97 | $15.62 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $15.35 | $7.16 |
| 52 Week High | $22.59 | $15.04 |
| Indicator | BWB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 48.86 |
| Support Level | $20.79 | $8.26 |
| Resistance Level | $21.91 | $12.06 |
| Average True Range (ATR) | 0.60 | 0.57 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 82.32 | 64.45 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.